Johnson & Johnson Reports IMAAVY Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Clinical Trial Results: Johnson & Johnson's Phase 2/3 ENERGY study demonstrates that the 30 mg/kg dose of IMAAVY achieves approximately three times the durable hemoglobin response in patients with warm autoimmune hemolytic anemia compared to placebo over 24 weeks, marking a significant breakthrough in a condition with no FDA-approved treatment options.
- Rapid Onset of Effect: Patients treated with IMAAVY showed an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating the drug's quick efficacy, which could significantly alleviate debilitating fatigue and improve quality of life for patients.
- Safety Profile: The study indicates that IMAAVY's safety profile aligns with its established safety in generalized myasthenia gravis, with common adverse reactions including peripheral edema, diarrhea, and fever, and no new safety signals identified, enhancing confidence in its clinical application.
- FDA Priority Review: These findings support the supplemental Biologics License Application (sBLA) for IMAAVY, which has been granted FDA Priority Review, indicating potential market opportunities for the drug in treating warm autoimmune hemolytic anemia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 237.000
Low
190.00
Averages
218.50
High
240.00
Current: 237.000
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson's IMAAVY Study Shows Significant Hemoglobin Improvement
- Clinical Trial Results: The Phase 2/3 ENERGY study demonstrated that IMAAVY (nipocalimab-aahu) produced a statistically significant durable hemoglobin response in the 30 mg/kg treatment group, with patients showing an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating rapid efficacy.
- Comparison to Placebo: Approximately three times as many patients in the IMAAVY group achieved durable hemoglobin levels by 24 weeks compared to the placebo group, highlighting the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- Fatigue Improvement and Steroid Reduction: The study also noted positive effects in fatigue improvement and reduction in steroid use, with nearly two-thirds of patients reaching the targets of hemoglobin ≥10 g/dL and an increase of ≥2 g/dL by Week 24.
- Safety and Regulatory Progress: IMAAVY's safety profile was consistent with its established safety in approved indications, with no new safety signals reported, supporting its supplemental Biologics License Application (sBLA) to the FDA, which has been granted Priority Review.
See More
Johnson & Johnson Reports IMAAVY Study Results
- Clinical Trial Results: Johnson & Johnson's Phase 2/3 ENERGY study demonstrates that the 30 mg/kg dose of IMAAVY achieves approximately three times the durable hemoglobin response in patients with warm autoimmune hemolytic anemia compared to placebo over 24 weeks, marking a significant breakthrough in a condition with no FDA-approved treatment options.
- Rapid Onset of Effect: Patients treated with IMAAVY showed an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating the drug's quick efficacy, which could significantly alleviate debilitating fatigue and improve quality of life for patients.
- Safety Profile: The study indicates that IMAAVY's safety profile aligns with its established safety in generalized myasthenia gravis, with common adverse reactions including peripheral edema, diarrhea, and fever, and no new safety signals identified, enhancing confidence in its clinical application.
- FDA Priority Review: These findings support the supplemental Biologics License Application (sBLA) for IMAAVY, which has been granted FDA Priority Review, indicating potential market opportunities for the drug in treating warm autoimmune hemolytic anemia.
See More
Jury Awards $32 Million to Family in Johnson & Johnson Mesothelioma Case
- Jury Verdict: A Los Angeles jury awarded $32 million to the family of a California woman who died from pleural mesothelioma due to exposure to asbestos-contaminated talc, clearly establishing corporate liability for Johnson & Johnson and its subsidiaries.
- Case Background: Maria Lozano passed away from mesothelioma in 2024, and her family continued the lawsuit posthumously, emphasizing her regular use of Johnson & Johnson's talc-based baby powder since the early 1970s, which ultimately led to her fatal cancer.
- Evidence Presentation: During the trial, the family's attorneys demonstrated that Johnson & Johnson failed to adequately warn consumers about the dangers of asbestos-contaminated talc, despite the company's longstanding knowledge of the associated risks, leading the jury to reject the company's environmental defense.
- Liability Findings: The jury determined that Maria's cancer was caused by her prolonged exposure to Johnson's Baby Powder, assigning 0% fault to other potential exposure sources such as environmental conditions in Mexico City and cosmetic products, reflecting the jury's trust in the evidence presented by the plaintiffs.
See More
Chip Stocks Slide as Oracle Prepares for Earnings Report
- Oracle Earnings Expectations: Oracle's stock has surged nearly 36% over the past three months, with an anticipated post-earnings move of 12%, indicating cautious optimism among investors that could influence market sentiment.
- Pharmaceutical Sector Dynamics: The S&P Health Care Index rose 1.3% on Tuesday, although it is down 3.5% from February highs, while the Pharma, Biotech, and Life Sciences sector has increased by 8.6% in the last month, reflecting investor confidence in this area.
- Target Stock Fluctuations: Target shares have risen 52% since the November low, gaining 2% on Tuesday, yet are down 5% from the April 21 high, highlighting the volatility and attention on retail stocks in the current market.
- Italy ETF Performance: The iShares MSCI Italy ETF hit a new high on Tuesday, ultimately closing up 1.5%, but has increased by 11% over the past three months, showcasing the recovery potential of the Italian market.
See More
Investors Take Profits, Tech Stocks Pull Back
- Market Pullback Reasons: Stocks are retreating as investors take profits in technology and AI infrastructure stocks, particularly after the S&P 500 rose about 1% shortly after the open before reversing, indicating market fragility.
- Investment Strategy Adjustment: To prepare for the upcoming SpaceX IPO, investors are freeing up capital, prompting us to trim positions in Goldman Sachs and Qnity Electronics on Monday to lock in substantial gains, reflecting market sensitivity to new supply.
- Dividend Adjustment Impact: FedEx announced a 5% increase in its annual dividend, but due to a one-time adjustment related to the FedEx Freight spin-off, the new quarterly payment is $1.22 per share, down from $1.45 in April, although the yield remains around 1.5%, demonstrating the company's commitment to shareholder returns.
- Economic Data Focus: The most significant economic readout this week is the May consumer price index, expected to rise 0.5% month-over-month and 4.2% year-over-year, with the core index projected to increase 2.9% year-over-year, which will influence market expectations regarding the Fed's future rate hikes, especially following a strong jobs report.
See More
SpaceX IPO Heats Up Amid Market Recovery
- Market Recovery: U.S. stocks are set for a higher open, with the S&P 500 and Nasdaq poised to recover some ground after last Friday's massive selloff, supported by lower oil prices and bond yields, indicating improved market sentiment.
- SpaceX IPO Surge: Bloomberg reports that SpaceX's IPO is well oversubscribed, with institutional investors placing orders for $10 billion worth of shares, and while institutional orders are expected to close after Wednesday, retail investors can still participate, reflecting strong market interest in the offering.
- Accelerated AI Investment: China plans to spend $295 billion over the next five years to build AI data centers, aiming to enhance its competitiveness against the U.S. by creating interconnected digital hubs that provide broader access to computing power, highlighting the global emphasis on AI technology.
- GSK Acquisition Plans: GSK announced plans to acquire U.S. drugmaker Nuvalent for $10.6 billion, resulting in a nearly 39% surge in Nuvalent's shares, indicating active merger activity in the pharmaceutical sector and potentially providing GSK with new growth opportunities.
See More
Johnson & Johnson's IMAAVY Study Shows Significant Hemoglobin Improvement
- Clinical Trial Results: The Phase 2/3 ENERGY study demonstrated that IMAAVY (nipocalimab-aahu) produced a statistically significant durable hemoglobin response in the 30 mg/kg treatment group, with patients showing an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating rapid efficacy.
- Comparison to Placebo: Approximately three times as many patients in the IMAAVY group achieved durable hemoglobin levels by 24 weeks compared to the placebo group, highlighting the drug's potential in treating warm autoimmune hemolytic anemia (wAIHA).
- Fatigue Improvement and Steroid Reduction: The study also noted positive effects in fatigue improvement and reduction in steroid use, with nearly two-thirds of patients reaching the targets of hemoglobin ≥10 g/dL and an increase of ≥2 g/dL by Week 24.
- Safety and Regulatory Progress: IMAAVY's safety profile was consistent with its established safety in approved indications, with no new safety signals reported, supporting its supplemental Biologics License Application (sBLA) to the FDA, which has been granted Priority Review.
See More
Johnson & Johnson Reports IMAAVY Study Results
- Clinical Trial Results: Johnson & Johnson's Phase 2/3 ENERGY study demonstrates that the 30 mg/kg dose of IMAAVY achieves approximately three times the durable hemoglobin response in patients with warm autoimmune hemolytic anemia compared to placebo over 24 weeks, marking a significant breakthrough in a condition with no FDA-approved treatment options.
- Rapid Onset of Effect: Patients treated with IMAAVY showed an average hemoglobin increase of at least 1 g/dL as early as Week 1, indicating the drug's quick efficacy, which could significantly alleviate debilitating fatigue and improve quality of life for patients.
- Safety Profile: The study indicates that IMAAVY's safety profile aligns with its established safety in generalized myasthenia gravis, with common adverse reactions including peripheral edema, diarrhea, and fever, and no new safety signals identified, enhancing confidence in its clinical application.
- FDA Priority Review: These findings support the supplemental Biologics License Application (sBLA) for IMAAVY, which has been granted FDA Priority Review, indicating potential market opportunities for the drug in treating warm autoimmune hemolytic anemia.
See More
Jury Awards $32 Million to Family in Johnson & Johnson Mesothelioma Case
- Jury Verdict: A Los Angeles jury awarded $32 million to the family of a California woman who died from pleural mesothelioma due to exposure to asbestos-contaminated talc, clearly establishing corporate liability for Johnson & Johnson and its subsidiaries.
- Case Background: Maria Lozano passed away from mesothelioma in 2024, and her family continued the lawsuit posthumously, emphasizing her regular use of Johnson & Johnson's talc-based baby powder since the early 1970s, which ultimately led to her fatal cancer.
- Evidence Presentation: During the trial, the family's attorneys demonstrated that Johnson & Johnson failed to adequately warn consumers about the dangers of asbestos-contaminated talc, despite the company's longstanding knowledge of the associated risks, leading the jury to reject the company's environmental defense.
- Liability Findings: The jury determined that Maria's cancer was caused by her prolonged exposure to Johnson's Baby Powder, assigning 0% fault to other potential exposure sources such as environmental conditions in Mexico City and cosmetic products, reflecting the jury's trust in the evidence presented by the plaintiffs.
See More
Chip Stocks Slide as Oracle Prepares for Earnings Report
- Oracle Earnings Expectations: Oracle's stock has surged nearly 36% over the past three months, with an anticipated post-earnings move of 12%, indicating cautious optimism among investors that could influence market sentiment.
- Pharmaceutical Sector Dynamics: The S&P Health Care Index rose 1.3% on Tuesday, although it is down 3.5% from February highs, while the Pharma, Biotech, and Life Sciences sector has increased by 8.6% in the last month, reflecting investor confidence in this area.
- Target Stock Fluctuations: Target shares have risen 52% since the November low, gaining 2% on Tuesday, yet are down 5% from the April 21 high, highlighting the volatility and attention on retail stocks in the current market.
- Italy ETF Performance: The iShares MSCI Italy ETF hit a new high on Tuesday, ultimately closing up 1.5%, but has increased by 11% over the past three months, showcasing the recovery potential of the Italian market.
See More
Investors Take Profits, Tech Stocks Pull Back
- Market Pullback Reasons: Stocks are retreating as investors take profits in technology and AI infrastructure stocks, particularly after the S&P 500 rose about 1% shortly after the open before reversing, indicating market fragility.
- Investment Strategy Adjustment: To prepare for the upcoming SpaceX IPO, investors are freeing up capital, prompting us to trim positions in Goldman Sachs and Qnity Electronics on Monday to lock in substantial gains, reflecting market sensitivity to new supply.
- Dividend Adjustment Impact: FedEx announced a 5% increase in its annual dividend, but due to a one-time adjustment related to the FedEx Freight spin-off, the new quarterly payment is $1.22 per share, down from $1.45 in April, although the yield remains around 1.5%, demonstrating the company's commitment to shareholder returns.
- Economic Data Focus: The most significant economic readout this week is the May consumer price index, expected to rise 0.5% month-over-month and 4.2% year-over-year, with the core index projected to increase 2.9% year-over-year, which will influence market expectations regarding the Fed's future rate hikes, especially following a strong jobs report.
See More
SpaceX IPO Heats Up Amid Market Recovery
- Market Recovery: U.S. stocks are set for a higher open, with the S&P 500 and Nasdaq poised to recover some ground after last Friday's massive selloff, supported by lower oil prices and bond yields, indicating improved market sentiment.
- SpaceX IPO Surge: Bloomberg reports that SpaceX's IPO is well oversubscribed, with institutional investors placing orders for $10 billion worth of shares, and while institutional orders are expected to close after Wednesday, retail investors can still participate, reflecting strong market interest in the offering.
- Accelerated AI Investment: China plans to spend $295 billion over the next five years to build AI data centers, aiming to enhance its competitiveness against the U.S. by creating interconnected digital hubs that provide broader access to computing power, highlighting the global emphasis on AI technology.
- GSK Acquisition Plans: GSK announced plans to acquire U.S. drugmaker Nuvalent for $10.6 billion, resulting in a nearly 39% surge in Nuvalent's shares, indicating active merger activity in the pharmaceutical sector and potentially providing GSK with new growth opportunities.
See More
